PET probes beyond 18F-FDG

Journal of Biomedical Research

Volumn 28, Issue 6, 2014, Pages 435-446

  Jiang, Lei ^a,b   Tu, Yingfeng ^b   Shi, Hongcheng ^a   Cheng, Zhen ^b  

^a FUDAN UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Molecular probes; Personalized medicine; PET

Indexed keywords

3' FLUOROTHYMIDINE F 18; AMINO ACID; AMYLOID BETA PROTEIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

AMINO ACID METABOLISM; CARDIAC IMAGING; FEASIBILITY STUDY; HUMAN; MOLECULAR IMAGING; MOLECULAR PROBE; NEUROIMAGING; ONCOLOGICAL PROCEDURE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREND STUDY; TUMOR GROWTH;

EID: 84928490101     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.28.20130196     Document Type: Review

References (81)

1. Vallabhajosula S, Solnes L, Vallabhajosula B. A broad overview of positron emission tomography radiopharma-ceuticals and clinical applications: what is new? Semin Nucl Med 2011;41:246-64.
2. Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 2011;38:70-86.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
4. Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP, et al. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol 2007;188:1109-13.
5. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79.
6. Ido T, Wan CN, Fowler JS. Fluorination with F2: convenient synthesis of 2-deoxy-2-fluoro-d-glucose. J Org Chem 1977;42:2341-2.
7. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
8. Füchtner F, Steinbach J, Mäding P. Basic previous term hydrolysis next term 2-[18F]fluoro-1,3,4,6-tetra-O-acetylimage-glucose in the preparation of 2-[18F]fluoro-2-deoxy-Image-glucose. Appl Radiat Isot 1996;47:61-6.
9. Chen K, Conti PS. Target-specific delivery of peptidebased probes for PET imaging. Adv Drug Deliv Rev 2010;62:1005-22.
10. Kayani I, Groves AM. 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 2006;6:240-4.
11. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;2785-808.
12. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in Oncology. Radiology 2004;231:305-32.
13. Josephs D, Spicer J, O'Doherty M. Molecular imaging in clinical trials. Target Oncol 2009;4:151-68.
14. Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, et al. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 2010;37:727-40.
15. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45.
16. Kubota K, Matsuzawa T, Ito M, Ito K, Fujiwara T, Abe Y, Yoshioka S, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985;26:37-42.
17. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998;25:1261-9.
18. Koizumi M, Saga T, Yoshikawa K, Suzuki K, Yamada S, Hasebe M, et al. L-[11C]methyl-methionine positron emission tomography for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol 2008;10:374-80.
19. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-9.
20. Christman D, Crawford EJ, Friedkin M, Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting methyl-[C-11]-thymidine. Proc Natl Acad Sci U S A 1972;69:988-92.
21. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44:1432-4.
22. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49:64S-80S.
23. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3-deoxy-3-[18F]fluorothymidine. Semin Nucl Med 2007;37:429-39.
24. Saga T, Koizumi M, Inubushi M, Yoshikawa K, Tanimoto K, Fukumura T, et al. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. Nucl Med Commun 2011;32:348-55.
25. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31:1659-72.
26. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
27. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18-FFDG. J Nucl Med 2005;46:945-52.
28. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 2006;31:774-80.
29. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, Lee SW, et al. Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006;33:412-9.
30. 18F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1223-32.
31. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80.
32. Lee ST, Scott AM. Hypoxia positron emission tomography imagimg with 18F-fluoromisonidazole. Semin Nucl Med 2007;37:451-61.
33. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60.
34. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41.
35. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
36. Havelund BM, Holdgaard PC, Rafaelsen SR, Mortensen LS, Theil J, Bender D, et al. Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun 2013;34:155-61.
37. Chitneni SK, Bida GT, Yuan H, Palmer GM, Hay MP, Melcher T, et al. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a nonsmall cell lung cancer xenograft model. J Nucl Med 2013;54:1339-46.
38. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60.
39. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002;45:1420-31.
40. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med 2009;50:1948-53.
41. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 1999;40:184-91.
42. Haas RL, de Jong D, Olmos RA, Hoefnagel CA, van den Heuvel I, Zerp SF, et al. In vivo imaging of radiationinduced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004;59:782-7.
43. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-Annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005;46:658-66.
44. Cheng Q, Lu L, Grafström J, Olofsson MH, Thorell JO, Samen E, Johansson K, et al. Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS One 2012;7:e42151.
45. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
46. Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, et al. Role of the avb3 integrin in human melanoma cell invasion. Pro Natl Acad Sci USA 1992;89:1557-61.
47. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X. Nearinfrared fluorescent RGD peptides for optical imaging of integrin αvß3 expression in living mice. Bioconjug Chem 2005;16:1433-41.
48. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Culabeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48:1162-71.
49. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009;20:2199-213.
50. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, et al. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing avb3 integrin. J Nucl Med 2010;51:251-8.
51. Chin FT, Shen B, Liu S, Berganos RA, Chang E, Mittra E, et al. First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET Studies. Mol Imaging Biol 2012;14:88-95.
52. Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging 2011;38:1732-41.
53. Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, Ding H, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 2013;54:691-8.
54. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
55. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2007;36:228-247.
56. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007:508-18.
57. Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, et al. PET/CT in cancer research: from preclinical to clinical applications. Contrast Media Mol Imaging 2010;5:190-200.
58. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imag 2008;35:186-208.
59. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11CPD153035 in humans. J Nucl Med 2009;50:303-8.
60. Fredriksson A, Johnstrom P, Thorell JO, von Heijne G, Hassan M, Eksborg S, et al. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999;65:165-74.
61. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007;13:527-34.
62. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008;44:2781-90.
63. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:121-36.
64. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11Clabeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54.
65. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-19.
66. Kung M-P, Hou C, Zhuang Z-P, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 2004;1025:98-105.
67. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
68. Kilbourn MR. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 1997;24:615-9.
69. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinsons's disease and normal aging. Ann Neurol 1996;40:873-84.
70. Kung M-P, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007;34:239-46.
71. Schelbert HR. Positron emission tomography of the heart: methodology, findings in the normal and disease heart, and clinical applications, in Phelps ME, (ed): PET: Molecular Imaging and Its Clinical Applications. New York, Springer, 2004.
72. Lin JW, Sciacca RR, Chou RL, Laine AF, Bergmann SR. Quantification of myocardial perfusion in human subjects using 82 Rb and wavelet-based noise reduction. J Nucl Med 2001;42:201-8.
73. Yalamanchili P, Wexler E, Hayes M, Yu M, Bozek J, Kagan M, et al. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol 2007;14:782-8.
74. Yu M, Mistry M, Guaraldi M. [18F]-RP1012: a novel myocardial perfusion imaging agent for use with positron emission tomography (PET). Circulation 2005;112:11-761.
75. Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of uptake of the new PET imaging compound 18 F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med 2006;47:1359-66.
76. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol 2007;14:789-98.
77. Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med 2011;52:1490-8.
78. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol 2010;65:500-16.
79. Agdeppa ED, Spilker ME. A review of imaging agent development. AAPS J 2009;11:286-99.
80. Centers for Medicare&Medicaid Services, Office of the Actuary. National Health Expenditure Projections 2011-2021: http://www.cms.gov/Research-Statistics-Dataand-Systems/Statistics-Trends-and-Reports/NationalHealth ExpendData/Downloads/Proj2011PDF.pdf, 2012.
81. O'Donnell M, Wei CW, Xia J, Pelivanov I, Jia C, Huang SW, et al. Can Molecular Imaging Enable Personalized Diagnostics? An Example Using Magnetomotive Photoacoustic Imaging. Ann Biomed Eng 2013;41:2237-47.